Sebastian SA, Padda I, Johal G
The Cleveland Clinic draws an important line: theres a difference between microdosing compounded versions of GLP-1s and working with your doctor to adjust the dose of an FDA-approved medication
Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications
Ongoing Monitoring: Regular follow-ups help assess effectiveness, monitor safety, and adjust the protocol when required
Data suggests that this could involve modulation of urea cycle enzymes in the liver and changes in messenger RNA expression